InMed Pharmaceuticals, Inc. (INM)
1.33
-0.02
(-1.48%)
USD |
NASDAQ |
Oct 02, 16:00
1.333
0.00 (0.00%)
After-Hours: 20:00
InMed Pharmaceuticals EPS Diluted (Quarterly) : -1.434 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -1.434 |
| March 31, 2026 | -0.7327 |
| December 31, 2025 | -0.5129 |
| September 30, 2025 | -0.4367 |
| June 30, 2025 | -0.8932 |
| March 31, 2025 | -1.935 |
| December 31, 2024 | -3.644 |
| September 30, 2024 | -2.706 |
| June 30, 2024 | -4.345 |
| March 31, 2024 | -3.584 |
| December 31, 2023 | -3.708 |
| September 30, 2023 | -15.24 |
| June 30, 2023 | -2.033 |
| March 31, 2023 | -12.01 |
| December 31, 2022 | -18.27 |
| September 30, 2022 | -81.10 |
| June 30, 2022 | -6047.66 |
| March 31, 2022 | -122.80 |
| December 31, 2021 | -154.64 |
| September 30, 2021 | -123.33 |
| June 30, 2021 | -202.39 |
| March 31, 2021 | -205.42 |
| December 31, 2020 | -141.34 |
| September 30, 2020 | -153.15 |
| June 30, 2020 | -154.77 |
| Date | Value |
|---|---|
| March 31, 2020 | -193.88 |
| December 31, 2019 | -243.12 |
| September 30, 2019 | -281.87 |
| June 30, 2019 | -305.60 |
| March 31, 2019 | -252.83 |
| December 31, 2018 | -194.03 |
| September 30, 2018 | -209.94 |
| June 30, 2018 | -255.58 |
| March 31, 2018 | -130.45 |
| December 31, 2017 | -129.79 |
| September 30, 2017 | -131.64 |
| June 30, 2017 | -180.26 |
| March 31, 2017 | -124.67 |
| December 31, 2016 | -123.65 |
| September 30, 2016 | -126.50 |
| June 30, 2016 | -127.99 |
| March 31, 2016 | -120.11 |
| December 31, 2015 | -123.57 |
| September 30, 2015 | -126.11 |
| June 30, 2015 | -336.67 |
| March 31, 2015 | -531.84 |
| December 31, 2014 | -145.29 |
| September 30, 2014 | -303.20 |
| June 30, 2014 | -453.87 |
| March 31, 2014 | -45.32 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| NervGen Pharma Corp. | -0.2283 |
| Milestone Pharmaceuticals, Inc. | -0.2063 |
| Clearmind Medicine, Inc. | -0.5734 |
| Lexaria Bioscience Corp. | -1.204 |
| Target Group, Inc. (Canada) | -0.0004 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -4.843M |
| Total Expenses (Quarterly) | 4.843M |
| Enterprise Value | 4.867M |
| Earnings Yield | -234.3% |
| Normalized Earnings Yield | -214.48 |